Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.1
3.0
Journals
JPM
Special Issues
Psoriasis: Pathology, Clinical Presentation, and Treatment
share announcement

Psoriasis: Pathology, Clinical Presentation, and Treatment

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Mechanisms of Diseases".

Deadline for manuscript submissions: closed (10 October 2022) | Viewed by 5084

Special Issue Editor

Dr. Raffaella Cascella

E-Mail Website
Guest Editor
1. Department of Biomedicine and Prevention, School of Medicine, University of Rome “Tor Vergata”, Rome, Italy
2. Department of Biomedical Sciences, Catholic University Our Lady of Good Counsel, 1000 Tirana, Albania
Interests: precision medicine; genomics; epigenomics; biomarkers investigations; genetics in retinal diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Psoriasis is a chronic immune-mediated inflammatory skin disease with a prevalence of 2–3% worldwide. Psoriasis is described as multifactorial disorder in which environmental and genetic/epigenetic factors are likely to influence the susceptibility to the disease. Despite the identification of different etiopathogenetic mechanisms involved in the onset and progression of the disease, many pieces are still missing to obtain a complete knowledge of this disease. On this subject, the identification of new biomarkers (preclinical, clinical, genomic, epigenomic, pharmacogenomic) and the possibility of applying precision medicine protocols to psoriasis could improve patients’ healthcare by providing the optimal therapeutic strategy and reducing the disease progression. In fact, precision medicine protocols will aim to optimize diagnostic procedures, treatment options, and the development of new therapeutic strategies. This Special Issue aims to highlight the role of personalized medicine in clinical practice, providing a complete overview of the disease and highlighting its critical issues in its management.

Dr. Raffaella Cascella
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • psoriasis
  • psoriatic arthritis
  • genomics and epigenomics
  • pathogenesis and pathophysiology
  • comorbidities
  • personalized medicine
  • bioinformatic and biostatistical approaches
  • microbiome
  • therapies

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 1031 KiB  
Article
Vitamin D May Be Connected with Health-Related Quality of Life in Psoriasis Patients Treated with Biologics
by Iulia-Alexandra Paliu, Simona-Laura Ianosi, Adina Turcu-Stiolica, Catalina-Gabriela Pisoschi, Luminita-Georgeta Predoi and Andrei-Adrian Tica
J. Pers. Med. 2022, 12(11), 1857; https://doi.org/10.3390/jpm12111857 - 7 Nov 2022
Viewed by 1629
Abstract
Suboptimal states of vitamin D may play a role in psoriasis evolution, but the interconnections have been studied over the past years with controversial results. Although a peerless therapy among moderate to severe types of psoriasis, the therapeutic effectiveness of biological therapy may [...] Read more.
Suboptimal states of vitamin D may play a role in psoriasis evolution, but the interconnections have been studied over the past years with controversial results. Although a peerless therapy among moderate to severe types of psoriasis, the therapeutic effectiveness of biological therapy may vary unforeseeably between patients and leads to biologics switch. We conducted a pilot study in patients diagnosed with psoriasis and treated with biologics, the purpose of which was to explore the prevalence of suboptimal states of vitamin D, especially in the group of patients characterized by the failure of previous biologics, and to investigate the associations between vitamin D levels and psoriasis, regarding aspects such the severity of the disease and quality of life. Their current result of latent tuberculosis infection (LTBI) was also considered concerning a feasible relationship with vitamin D levels. From July to December 2021, 45 patients corresponding to our inclusion criteria were assessed. Variables such as Psoriasis Area and Severity Index (PASI) score and the Dermatology Life Quality Index (DLQI) score, as well as vitamin D serum concentrations and their LTBI result, were recorded for them. Lower serum concentrations of vitamin D were not more common in patients characterized by failure to previous biologics (p = 0.443), but we concluded a weak correlation between the DLQI score and vitamin D (rho = −0.345, p-value = 0.020), although a statistically insignificant result was obtained between vitamin D and the PASI score (rho = −0.280, p-value = 0.062), and with the LTBI result (rho = −0.053, p-value = 0.728). These results establish a connection between higher levels of vitamin D and a better outcome of psoriasis from the perspective of the patient’s quality of life, with no significant association with psoriasis severity and no significant prevalence of suboptimal states among patients that failed previous biologics compared to those with a continuously good response. Full article
(This article belongs to the Special Issue Psoriasis: Pathology, Clinical Presentation, and Treatment)
►▼ Show Figures

Figure 1

7 pages, 250 KiB  
Article
Psychological Stress and Salivary Cortisol Levels in Patients with Plaque Psoriasis
by Paolo Gisondi, Davide Geat, Francesco Bellinato, Laura Spiazzi, Elisa Danese, Martina Montagnana, Giuseppe Lippi and Giampiero Girolomoni
J. Pers. Med. 2021, 11(11), 1069; https://doi.org/10.3390/jpm11111069 - 23 Oct 2021
Cited by 5 | Viewed by 2625
Abstract
Psychological stress has long been recognized as a trigger for plaque psoriasis, and preliminary evidence suggests that psoriasis could be associated with alterations in the hypothalamic-pituitary-adrenal (HPA) axis, resulting in impaired cortisol response to stress. This study aimed to investigate psychological stress, anxiety, [...] Read more.
Psychological stress has long been recognized as a trigger for plaque psoriasis, and preliminary evidence suggests that psoriasis could be associated with alterations in the hypothalamic-pituitary-adrenal (HPA) axis, resulting in impaired cortisol response to stress. This study aimed to investigate psychological stress, anxiety, depression and salivary cortisol in psoriatic patients. A cross sectional study involving 126 adult patients with plaque psoriasis and 116 adult healthy controls was conducted. Demographic, clinical data, Perceived Stress Scale (PSS) and Hospital Anxiety and Depression Scale (HADS) were collected. Cases and controls were asked whether they felt stressed in the last month, whilst psoriatic patients were also interrogated whether they found that psoriasis could have been worsened by stress. Moreover, 54 randomly selected subjects (27 psoriasis patients and 27 controls) underwent salivary cortisol testing at 8 am. PSS, HADS depression and anxiety subscales were significantly higher in psoriatic patients than in controls (17.2 ± 0.6 vs. 15.1 ± 0.8 p = 0.0289), (9.5 ± 0.3 vs. 6.2 ± 0.3 p < 0.001) and (8.2 ± 0.4 vs. 4.2 ± 0.3 p < 0.001), respectively. A higher rate of psoriatic patients reported feeling stress over the last month (45% vs. 19%, p < 0.001), and stress was considered a potential trigger for psoriasis flare-ups in 69% of cases. Psoriasis was strongly associated with higher PSS and HADS scores independently of sex, body mass index, diabetes, hypertension, dyslipidemia, and occupational status. Salivary cortisol was significantly lower in psoriatic patients compared to controls (9.6 ± 0.5 vs. 14.0 ± 1.1 nmol/L, p < 0.001). In conclusion, psoriasis was associated with higher psychological stress, anxiety and depressive symptoms, and with impaired cortisol response to stress. Full article
(This article belongs to the Special Issue Psoriasis: Pathology, Clinical Presentation, and Treatment)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop